216 related articles for article (PubMed ID: 16189117)
1. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Kaniga K; Krause KM; Shelton J; Obedencio GP; Gough A; Conner M; Hegde SS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4344-6. PubMed ID: 16189117
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
Hegde SS; Reyes N; Skinner R; Difuntorum S
J Antimicrob Chemother; 2008 Jan; 61(1):169-72. PubMed ID: 17993505
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Benton BM; Krause KM; Shelton J; Obedencio GP; Hegde SS
J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
8. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
9. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Pawlak J; Johnson LB
J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
[TBL] [Abstract][Full Text] [Related]
13. Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
Kanafani ZA
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):743-9. PubMed ID: 17140351
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.
Stucki A; Gerber P; Acosta F; Cottagnoud M; Cottagnoud P
Antimicrob Agents Chemother; 2006 Feb; 50(2):770-3. PubMed ID: 16436742
[TBL] [Abstract][Full Text] [Related]
17. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
18. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infections caused by resistant Staphylococcus aureus.
Anstead GM; Quinones-Nazario G; Lewis JS
Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
[TBL] [Abstract][Full Text] [Related]
20. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
